Contributors
Vikram Arora(G1 Therapeutics (United States)), Jayanthi Wolf, Marque D. Todd, Padma Kumar Narayanan(Wave Life Sciences (United States)), Maggie Dempster(GlaxoSmithKline (United States)), Joy Cavagnaro(Access to Wholistic and Productive Living Institute), Danuta J. Herzyk, Christina de Zafra, Gautham K. Rao(Bristol-Myers Squibb (United States)), Melinda Marian, Justine J. Cunningham(Regenxbio (United States)), Rania Nasis, Wolfgang Seghezzi, Barbara Mounho-Zamora, Lisa M. Plitnick, Anu Connor(Ipsen (United States)), Timothy K. MacLachlan(Novartis (United States)), Beth Hinkle, Theresa Reynolds, Rafael Ponce, Thomas Gelzleichter(Biogen (United States)), Donna W. Lee(Impact Assessment), Rodney A. Prell, Amy Kim, Deborah L. Novicki, Karen Price(Purchase College), Wendy Halpern(Roche (Switzerland)), Eugene P. Brandon(IQVIA (United States)), Inge A. Ivens(Bayer (United States))
Cited by 0
Related Papers
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
|Nature Biotechnology|2008|1.4k
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs
|Journal of Pharmaceutical Sciences|2016|707
Cancer Drug Discovery and Development
|Humana Press eBooks|2003|194
Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to Prolong Islet Allograft Survival
|The Journal of Immunology|2005|183